Skip to main content
Premium Trial:

Request an Annual Quote

Symyx Board Again Rejects Certara Bid

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Symyx Technologies said last night after the close of the market that its board of directors has once again rejected Certara's bid to acquire the firm for $5.75 per share, or around $200 million, saying that it does not constitute a superior offer to Accelrys' bid to acquire the company.

This is the second time this week that the Symyx board has rejected the Certara offer, which is higher than Acclerys' $5 per share bid. The Symyx board has stated that a combination with Accelrys offers a greater upside and has urged Symyx shareholders to support the Accelrys bid.

San Diego-based Accelrys issued a separate release last night saying that independent proxy advisory firm Institutional Shareholder Services has recommended Accelrys' shareholders vote in favor of the merger with Symyx next week.

Under the deal, shareholders of each firm would own roughly half of the combined life science informatics company. The firms expect full-year net synergies of between $10 million and $15 million, and annualized revenues of more than $160 million.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.